Long-term Remission of Wells Syndrome With Omalizumab.

Coattrenec, Y; Ibrahim Yasmine, L; Harr, T; Spoerl, D; Jandus, P

Coattrenec, Y; Ibrahim Yasmine, L; Harr, T; Spoerl, D; Jandus, P.

Afiliação

Coattrenec Y; Division of Immunology and Allergology, Department of Internal Medicine, University Hospital and Medical Faculty, Geneva, Switzerland.
Ibrahim Yasmine L; Division of Clinical Pathology, University Hospital and Medical Faculty, Geneva, Switzerland.
Harr T; Division of Immunology and Allergology, Department of Internal Medicine, University Hospital and Medical Faculty, Geneva, Switzerland.
Spoerl D; Division of Immunology and Allergology, Department of Internal Medicine, University Hospital and Medical Faculty, Geneva, Switzerland.
Jandus P; Division of Immunology and Allergology, Department of Internal Medicine, University Hospital and Medical Faculty, Geneva, Switzerland.

J Investig Allergol Clin Immunol ; 30(1): 58-59, 2020.

Article em En | MEDLINE | ID: mdl-31530507

Assuntos

Antialérgicos/uso terapêutico; Celulite (Flegmão)/tratamento farmacológico; Eosinofilia/tratamento farmacológico; Eosinófilos/imunologia; Omalizumab/uso terapêutico; Pele/patologia; Idoso; Eosinófilos/efeitos dos fármacos; Humanos; Masculino; Indução de Remissão; Pele/efeitos dos fármacos; Resultado do Tratamento

Palavras-chave

Eosinophilic cellulitis; Omalizumab; Successful treatment; Wells syndrome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pele / Celulite (Flegmão) / Antialérgicos / Eosinofilia / Eosinófilos / Omalizumab Limite: Aged / Humans / Male Idioma: En Revista: J Investig Allergol Clin Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google